Flavin-containing monooxygenases: mutations, disease and drug response

Trends in Pharmacological Sciences

Volumn 29, Issue 6, 2008, Pages 294-301

  Phillips, Ian R ^a   Shephard, Elizabeth A ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DIMETHYLANILINE MONOOXYGENASE; ETHIONAMIDE; IMIPRAMINE; ITOPRIDE; METHAMPHETAMINE; OLOPATADINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELEGILINE; SULINDAC SULFIDE; TAMOXIFEN; THIAMAZOLE; THIOACETAZONE;

DIMETHYLANILINE MONOOXYGENASE 3 GENE; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE; GENE CONTROL; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; NONSENSE MUTATION; PREDICTION; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; YEAST;

HUMANS; MUTATION; OXYGENASES; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; SCHIZOSACCHAROMYCES;

EID: 44549087470     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.03.004     Document Type: Review

References (76)

1. Krueger S.K., and Williams D.E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 106 (2005) 357-387
2. Cashman J.R., and Zhang J. Human flavin-containing monooxygenases. Annu .Rev. Pharmacol. Toxicol. 46 (2006) 65-100
3. Phillips I.R., et al. The flavin-containing monooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Curr. Pharmacogen. 5 (2007) 292-313
4. Koukouritaki S.B., and Hines R.N. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics 6 (2005) 807-822
5. Ziegler D.M. Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 179-199
6. Ziegler D.M. An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab. Rev. 34 (2002) 503-511
7. Eswaramoorthy S., et al. Mechanism of action of a flavin-containing monooxygenase. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9832-9837
8. Poulsen L.L., and Ziegler D.M. The liver microsomal FAD-containing monooxygenase. Spectral characterization and kinetic studies. J. Biol. Chem. 254 (1979) 6449-6455
9. Suh J.K., et al. Molecular cloning and kinetic characterization of a flavin-containing monooxygenase from Saccharomyces cerevisiae. Arch. Biochem. Biophys. 336 (1996) 268-274
10. Suh J.K., et al. Redox regulation of yeast flavin-containing monooxygenase. Arch. Biochem. Biophys. 381 (2000) 317-322
11. Lawton M.P., et al. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys. 308 (1994) 254-257
12. Phillips I.R., et al. The molecular biology of the flavin-containing monooxygenases of man. Chem. Biol. Interact. 96 (1995) 17-32
13. Hernandez D., et al. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14 (2004) 117-130
14. Hines R.N., et al. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol. Pharmacol. 62 (2002) 320-325
15. Dolphin C.T., et al. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat. Genet. 17 (1997) 491-494
16. Treacy E.P., et al. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum. Mol. Genet. 7 (1998) 839-845
17. Mitchell S.C., and Smith R.L. Trimethylaminuria: the fish malodor syndrome. Drug Metab. Dispos. 29 (2001) 517-521
18. Phillips, I.R. and Shephard, E.A. (2007) Trimethylaminuria. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2007. Available at http://www.genetests.org.
19. Mitchell S.C., et al. Studies on the discontinuous N-oxidation of trimethylamine among Jordanian, Ecuadorian and New Guinean populations. Pharmacogenetics 7 (1997) 45-50
20. Hernandez D., et al. Trimethylaminuria and a human FMO3 mutation database. Hum. Mut. 22 (2003) 201-213
21. Yeung C.K., et al. Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch. Biochem. Biophys. 464 (2007) 251-259
22. Mayatepek E., et al. Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics 14 (2004) 775-777
23. Cashman J.R., et al. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr. Drug. Metab. 4 (2003) 151-170
24. Chalmers R.A., et al. Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J. Inherit. Metab. Dis. 29 (2006) 162-172
25. Yamazaki H., et al. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci. 74 (2004) 2739-2747
26. Malaspina A., et al. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 77 (2001) 132-145
27. Cereda C., et al. Increased incidence of FMO1 gene single nucleotide polymorphisms in sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 7 (2006) 227-234
28. Kim Y.H., et al. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp. Mol. Med. 35 (2003) 336-349
29. Krueger S.K., et al. The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab. Rev. 38 (2006) 139-147
30. Qian L., and Ortiz de Montellano P.R. Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem. Res. Toxicol. 19 (2006) 443-449
31. Dolphin C., et al. Cloning, primary sequence, and chromosomal mapping of a human flavin-containing monooxygenase (FMO1). J. Biol. Chem. 266 (1991) 12379-12385
32. Dolphin C.T., et al. Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Eur. J. Biochem. 235 (1996) 683-689
33. Yeung C.K., et al. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab. Dispos. 28 (2000) 1107-1111
34. Jakobsson S.V., and Cintig D.L. Studies on the cytochrome P-450-containing mono-oxygenase system in human kidney cortex microsomes. J. Pharmacol. Exp. Ther. 185 (1973) 226-234
35. Shimada T., et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 (1994) 414-423
36. Koukouritaki S.B., et al. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res. 51 (2002) 236-243
37. Shephard E.A., et al. Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse. Biochem. J. 406 (2007) 491-499
38. Cashman J.R. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov. Today 9 (2004) 574-581
39. Koukouritaki S.B., et al. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J. Pharmacol. Exp. Ther. 320 (2007) 266-273
40. Lattard V., et al. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab. Dispos. 31 (2003) 854-860
41. Shimizu M., et al. Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. Drug Metab. Dispos. 35 (2007) 328-330
42. Brunelle A., et al. Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions. Drug Metab. Dispos. 25 (1997) 1001-1007
43. Sachse C., et al. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin. Pharmacol. Ther. 66 (1999) 431-438
44. Kang J.H., et al. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. Pharmacogenetics 10 (2000) 67-78
45. Cashman J.R., et al. Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab. Dispos. 29 (2001) 1629-1637
46. Park C.S., et al. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 12 (2002) 77-80
47. Mayatepek E., and Kohlmüller D. Transient trimethylaminuria in childhood. Acta. Paediatr. 87 (1998) 1205-1207
48. Zschocke J., et al. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 354 (1999) 834-835
49. Hisamuddin I.M., et al. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin. Cancer Res. 10 (2004) 8357-8362
50. Hisamuddin I.M., et al. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2366-2369
51. Duggan D.E., et al. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther. 201 (1977) 8-13
52. Etienne F., et al. Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Biochem. Biophys. Res. Commun. 312 (2003) 1005-1010
53. Hamman M.A., et al. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem. Pharmacol. 60 (2000) 7-17
54. Duggan D.E., et al. The disposition of sulindac. Clin. Pharmacol. Ther. 21 (1977) 326-335
55. Koukouritaki S.B., et al. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol. Pharmacol. 68 (2005) 383-392
56. Allerston C.K., et al. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet. Genomics 17 (2007) 827-839
57. Dolphin C.T., et al. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J. Biol. Chem. 273 (1998) 30599-30607
58. Whetstine J.R., et al. Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in african-americans. Toxicol. Appl. Pharmacol. 168 (2000) 216-224
59. Krueger S.K., et al. Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein. Drug Metab. Dispos. 30 (2002) 34-41
60. Veeramah, K. et al. The potentially deleterious functional variant FMO2*1 is at high frequency throughout sub-Saharan Africa. Pharmacogenet Genomics (in press)
61. Furnes B., et al. Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab. Dispos. 31 (2003) 187-193
62. Krueger S.K., et al. Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. Pharmacogenet. Genomics 15 (2005) 245-256
63. Henderson M.C., et al. S-oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human lung flavin-containing monooxygenase 2. Biochem. Pharmacol. 68 (2004) 959-967
64. Henderson M.C., et al. Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chem. Res. Toxicol. 17 (2004) 633-640
65. Furnes B., and Schlenk D. Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes. Toxicol. Sci. 78 (2004) 196-203
66. Hines R.N., et al. Genetic variability at the human FMO1 locus: significance of a basal promoter Yin Yang 1 element polymorphism (FMO1*6). J. Pharmacol. Exp. Ther. 306 (2003) 1210-1218
67. Luo Z., and Hines R.N. Regulation of flavin-containing monooxygenase 1 expression by Ying Yang 1 and hepatic nuclear factors 1 and 4. Mol. Pharmacol. 60 (2001) 1421-1430
68. Cashman J.R., et al. N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication. J. Pharmacol. Expt. Ther. 288 (1999) 1251-1260
69. Szoko E., et al. Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Electrophoresis 25 (2004) 2866-2875
70. Tugnait M., et al. N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab. Dispos. 25 (1997) 524-527
71. Parte P., and Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab. Dispos. 33 (2005) 1446-1452
72. Kim Y.M., and Ziegler D.M. Size limits of thiocarbamides accepted as substrates by human flavin- containing monooxygenase 1. Drug Metab. Dispos. 28 (2000) 1003-1006
73. Mushiroda T., et al. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab. Dispos. 28 (2000) 1231-1237
74. Kajita J., et al. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab. Dispos. 30 (2002) 1504-1511
75. Dolphin C.T., et al. Structural organization of the human flavin-containing monooxygenase 3 gene (FMO3), the favored candidate for fish-odor syndrome, determined directly from genomic DNA. Genomics 46 (1997) 260-267
76. Dolphin C.T., et al. Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome. Pharmacogenetics 10 (2000) 799-807